Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thalassaemia.

Nature reviews. Disease primers·2026

Same author

Targeting ineffective erythropoiesis in thalassemia: biologic therapies and emerging therapeutic strategies.

Expert opinion on biological therapy·2026

Same author

Addressing Obstetric and Gynecologic Needs in Thalassemia.

O&G open·2026

Same author

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026

Same author

When cure exists but access does not.

Nature medicine·2026

Same author

Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial.

European journal of haematology·2026

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Thalidomide and thrombosis. A meta-analysis.

Ramzi N El Accaoui¹, Wael A Shamseddeen, Ali T Taher

¹American University of Beirut Medical Center, P.O. Box 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon.

Thrombosis and Haemostasis

|June 6, 2007

Summary

Thalidomide and dexamethasone increase venous thromboembolic (VTE) event risk in multiple myeloma (MM) patients. Adequate anticoagulation significantly reduces this risk, highlighting the need for careful monitoring and prophylactic measures.

Related Experiment Videos

Last Updated: Jul 14, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

Hematology
Oncology
Pharmacology

Background:

Thalidomide use is increasing for various conditions, notably multiple myeloma (MM).
Reports suggest a potential link between thalidomide and increased venous thromboembolic (VTE) events.
Concomitant medications and anticoagulation strategies may influence VTE risk.

Purpose of the Study:

To assess the risk of VTE events associated with thalidomide in MM patients.
To determine if dexamethasone affects this VTE risk.
To evaluate the impact of anticoagulation and anti-platelet therapies on VTE events.

Main Methods:

A comprehensive literature search was conducted, reviewing 50 relevant articles.
A retrospective analysis was performed on a sample of 3,322 patients.
Multivariate logistic regression was utilized to analyze risk factors.

Main Results:

Thalidomide monotherapy increased VTE risk by 2.6 times.
Concomitant dexamethasone administration elevated VTE risk by 2.8 times.
The combination of thalidomide and dexamethasone increased VTE risk eightfold; adequate anticoagulation significantly reduced this risk.

Conclusions:

Thalidomide use in MM patients necessitates vigilant monitoring for VTE events.
Close observation is crucial for patients receiving thalidomide with dexamethasone or other chemotherapy.
Prophylactic anticoagulation (e.g., low-molecular-weight heparin, warfarin) effectively mitigates VTE risk in MM patients.